Spectral awaits broader cardiac patent:
This article was originally published in Clinica
Executive Summary
The US Patent Office says it will issue a new, broader cardiac panel testing patent to Spectral Diagnostics. Spectral's original 1994 patent covered panel tests using myoglobin, myosin light-chains and either CK-MB, troponin-I or troponin-T, in chest pain patients. The new patent will extend the range of analyte combinations and be independent of test format. New analytes include glycogen phosphorylase, fatty acid binding proteins and carbonic anhydrase, among others.